FDA delays decision on Sarepta's muscle-wasting disorder drug

[May 25, 2016]  (Reuters) - Sarepta Therapeutics Inc said it was notified by the U.S. Food and Drug Administration that a review of its muscle-wasting disorder drug would not be completed by Thursday.

The FDA said it will continue to work past the goal date and strive to complete the work in as timely a manner as possible.

The drug, eteplirsen, is under review for Duchenne muscular dystrophy, a devastating degenerative disease that mostly affects boys.

(Reporting by Amrutha Penumudi in Bengaluru; Editing by Don Sebastian)

[© 2016 Thomson Reuters. All rights reserved.]

Copyright 2016 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.